PDS Biotechnology (PDSB) News
NASDAQ: PDSBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
0.7774-0.0299 (-3.70%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PDSB news summary
We found 3 recent headlines mentioning PDS Biotechnology (PDSB): 0 in the past week and 1 in the past 30 days, most often from GlobeNewswire, Nasdaq. For price context, PDSB is down 3.70% at $0.7774. The most recent story, "PDS Biotech Reports Third Quarter 2026 Financial Results", was published by GlobeNewswire on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest PDS Biotechnology headlines
- PDS Biotech Reports Third Quarter 2026 Financial ResultsPRINCETON, N.J., Nov. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company focused on transforming how…GlobeNewswire
- PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of DirectorsJohn Dawson CBE, Deborah Ramsdell and Bruce Wendel bring corporate development, commercialization, and regulatory experience to the Company as it advances PDS0301 toward Phase 3 trial in Metastatic…GlobeNewswire
- 5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara(RTTNews) - Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3…NasdaqATRA, BJDX, PDSB, PHVS